Charles Schwab Dresdner RCM Global Dreyfus Fidelity Firsthand Capital Mgmt. MSDW Funds Oak Assoc. Best Small Cos.
Drug sales are the rocket towing drug giant's earnings skyward.
Singulair also showed impressive growth. But the rocket may run out of fuel. The drug giant, which employs more than 57,000 people, will lose its five best-selling drugs to patent expirations in the next two years. The loss of drugs like Vasotec and Prilosec will cost Merck billions, Ricardo says. Even with new drugs spiraling skyward, Merck may not be able to prevent those losses from slowing its ascent.